Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CD19x22 CAR T Cells for the Treatment of Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia

Trial Status: active

This phase I trial tests the safety, side effects, best dose, and effectiveness of CD19x22 chimeric antigen receptor (CAR) T cells in treating pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving CD19x22 CAR T cells may be safe, tolerable, and/or effective in treating pediatric patients with relapsed and/or refractory B-ALL.